Suchen
Amgen Inc
AMGNZur Watchlist hinzufügen
326.310USD
-7.400-2.22%
Handelsschluss 05/15, 16:00（ET）Kurse um 15 Minuten verzögert
176.11BMarktkapitalisierung
22.53KGV TTM
mehr Informationen über Amgen Inc Unternehmen
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Amgen Inc Informationen
BörsenkürzelAMGN
Name des UnternehmensAmgen Inc
IPO-datumJun 17, 1983
CEOBradway (Robert A)
Anzahl der mitarbeiter28000
WertpapierartOrdinary Share
GeschäftsjahresendeJun 17
AddresseOne Amgen Center Drive
StadtTHOUSAND OAKS
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl91320-1799
Telefon18054471000
Websitehttps://www.amgen.com/
BörsenkürzelAMGN
IPO-datumJun 17, 1983
CEOBradway (Robert A)
Führungskräfte von Amgen Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Robert A. (Bob) Bradway
Mr. Robert A. (Bob) Bradway
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
645.95K
+0.51%
Mr. Esteban Santos
Mr. Esteban Santos
Executive Vice President - Operations
Executive Vice President - Operations
75.13K
+0.59%
Mr. Murdo Gordon
Mr. Murdo Gordon
Executive Vice President - Global Commercial Operations
Executive Vice President - Global Commercial Operations
48.67K
+1.91%
Mr. Derek Miller
Mr. Derek Miller
Senior Vice President - Human Resources
Senior Vice President - Human Resources
12.07K
+2.25%
Ms. Rachna Khosla
Ms. Rachna Khosla
Senior Vice President - Business Development
Senior Vice President - Business Development
7.93K
+1.30%
Dr. Wanda M. Austin, Ph.D.
Dr. Wanda M. Austin, Ph.D.
Independent Director
Independent Director
7.35K
--
Ms. Nancy A. Grygiel
Ms. Nancy A. Grygiel
Senior Vice President, Chief Compliance Officer
Senior Vice President, Chief Compliance Officer
6.10K
-18.98%
Dr. Tyler Jacks
Dr. Tyler Jacks
Independent Director
Independent Director
3.45K
-398.93%
Dr. Brian J. Druker, M.D.
Dr. Brian J. Druker, M.D.
Independent Director
Independent Director
3.16K
-139.60%
Ms. Mary E. Klotman
Ms. Mary E. Klotman
Independent Director
Independent Director
719.00
-112.52%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Robert A. (Bob) Bradway
Mr. Robert A. (Bob) Bradway
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
645.95K
+0.51%
Mr. Esteban Santos
Mr. Esteban Santos
Executive Vice President - Operations
Executive Vice President - Operations
75.13K
+0.59%
Mr. Murdo Gordon
Mr. Murdo Gordon
Executive Vice President - Global Commercial Operations
Executive Vice President - Global Commercial Operations
48.67K
+1.91%
Mr. Derek Miller
Mr. Derek Miller
Senior Vice President - Human Resources
Senior Vice President - Human Resources
12.07K
+2.25%
Ms. Rachna Khosla
Ms. Rachna Khosla
Senior Vice President - Business Development
Senior Vice President - Business Development
7.93K
+1.30%
Dr. Wanda M. Austin, Ph.D.
Dr. Wanda M. Austin, Ph.D.
Independent Director
Independent Director
7.35K
--
Umsatzaufteilung
Währung: USDAktualisiert: Thu, Apr 2
Währung: USDAktualisiert: Thu, Apr 2
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Other products
7.26B
19.76%
Prolia
4.41B
12.01%
Repatha
3.02B
8.21%
Otezla
2.27B
6.16%
Enbrel
2.23B
6.06%
Andere
17.57B
47.80%
Nach RegionUSD
Name
Umsatz
Anteil
US
25.66B
69.81%
ROW
9.49B
25.83%
Other revenues
1.60B
4.36%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Other products
7.26B
19.76%
Prolia
4.41B
12.01%
Repatha
3.02B
8.21%
Otezla
2.27B
6.16%
Enbrel
2.23B
6.06%
Andere
17.57B
47.80%
Aktionärsstatistik
Aktualisiert: Sun, May 10
Aktualisiert: Sun, May 10
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Vanguard Capital Management, LLC
6.49%
State Street Investment Management (US)
5.67%
BlackRock Institutional Trust Company, N.A.
5.48%
Capital World Investors
4.28%
Capital International Investors
3.37%
Andere
74.71%
Aktionäre
Aktionäre
Anteil
Vanguard Capital Management, LLC
6.49%
State Street Investment Management (US)
5.67%
BlackRock Institutional Trust Company, N.A.
5.48%
Capital World Investors
4.28%
Capital International Investors
3.37%
Andere
74.71%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
54.36%
Investment Advisor/Hedge Fund
19.87%
Research Firm
4.52%
Pension Fund
2.17%
Bank and Trust
1.89%
Sovereign Wealth Fund
1.28%
Hedge Fund
0.65%
Insurance Company
0.61%
Individual Investor
0.18%
Andere
14.48%
Institutionelle Beteiligung
Aktualisiert: Wed, Apr 1
Aktualisiert: Wed, Apr 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q1
4665
460.83M
85.38%
+2.25M
2025Q4
4407
451.47M
85.20%
+63.91K
2025Q3
4486
451.61M
85.29%
-1.24M
2025Q2
4487
452.85M
84.91%
+2.52M
2025Q1
4500
450.78M
83.12%
+3.88M
2024Q4
4470
440.57M
82.15%
+6.55M
2024Q3
4290
435.41M
82.39%
-1.01M
2024Q2
4260
436.06M
82.34%
+1.04M
2024Q1
4169
435.45M
81.98%
-3.93M
2023Q4
4130
433.32M
81.14%
+5.55M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
State Street Investment Management (US)
30.59M
5.67%
+1.29M
+4.39%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
29.59M
5.49%
+1.06M
+3.71%
Dec 31, 2025
Capital World Investors
23.10M
4.28%
+4.30M
+22.89%
Dec 31, 2025
Capital International Investors
18.19M
3.37%
-1.01M
-5.25%
Dec 31, 2025
Geode Capital Management, L.L.C.
14.30M
2.65%
+1.04M
+7.81%
Dec 31, 2025
Charles Schwab Investment Management, Inc.
11.81M
2.19%
-1.74M
-12.84%
Dec 31, 2025
Invesco Capital Management (QQQ Trust)
11.45M
2.12%
-276.23K
-2.35%
Feb 28, 2026
Morgan Stanley Smith Barney LLC
9.15M
1.7%
+253.04K
+2.84%
Dec 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Mon, Dec 1
Aktualisiert: Mon, Dec 1
Name
Anteil
VanEck Biotech ETF
12.81%
FT Vest DJIA Dogs 10 Target Income ETF
12.23%
ProShares Ultra Nasdaq Biotechnology
8.42%
Invesco Nasdaq Biotechnology ETF
8.35%
Simplify Health Care ETF
7.93%
iShares Biotechnology ETF
7.08%
Invesco Dow Jones Industrial Average Dividend ETF
6.24%
Amplify Weight Loss Drug & Treatment ETF
5.87%
Invesco Pharmaceuticals ETF
5.05%
Invesco Biotechnology & Genome ETF
5.01%
Mehr Anzeigen
VanEck Biotech ETF
Anteil12.81%
FT Vest DJIA Dogs 10 Target Income ETF
Anteil12.23%
ProShares Ultra Nasdaq Biotechnology
Anteil8.42%
Invesco Nasdaq Biotechnology ETF
Anteil8.35%
Simplify Health Care ETF
Anteil7.93%
iShares Biotechnology ETF
Anteil7.08%
Invesco Dow Jones Industrial Average Dividend ETF
Anteil6.24%
Amplify Weight Loss Drug & Treatment ETF
Anteil5.87%
Invesco Pharmaceuticals ETF
Anteil5.05%
Invesco Biotechnology & Genome ETF
Anteil5.01%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
17.60B
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Mar 04, 2026
AMGN.NB Interim Cash Dividend of gross USD 2.52 paid on Jun 05, 2026 going ex on May 15, 2026
May 15, 2026
Jun 05, 2026
May 15, 2026
Dec 09, 2025
AMGN.NB Interim Cash Dividend of gross USD 2.52 paid on Mar 06, 2026 going ex on Feb 13, 2026
Feb 13, 2026
Mar 06, 2026
Feb 13, 2026
Oct 31, 2025
AMGN.NB Final Cash Dividend of gross USD 2.38 paid on Dec 12, 2025 going ex on Nov 21, 2025
Nov 21, 2025
Dec 12, 2025
Nov 21, 2025
Aug 01, 2025
AMGN.NB Interim Cash Dividend of gross USD 2.38 paid on Sep 12, 2025 going ex on Aug 22, 2025
Aug 22, 2025
Sep 12, 2025
Aug 22, 2025
Mar 04, 2025
AMGN.NB Interim Cash Dividend of gross USD 2.38 paid on Jun 06, 2025 going ex on May 16, 2025
May 16, 2025
Jun 06, 2025
May 16, 2025
Dec 10, 2024
AMGN.NB Interim Cash Dividend of gross USD 2.38 paid on Mar 07, 2025 going ex on Feb 14, 2025
Feb 14, 2025
Mar 07, 2025
Feb 14, 2025
Oct 25, 2024
AMGN.NB Final Cash Dividend of gross USD 2.25 paid on Dec 09, 2024 going ex on Nov 18, 2024
Nov 18, 2024
Dec 09, 2024
Nov 18, 2024
Aug 02, 2024
AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Sep 06, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Sep 06, 2024
Aug 16, 2024
Mar 06, 2024
AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Jun 07, 2024 going ex on May 16, 2024
May 17, 2024
Jun 07, 2024
May 16, 2024
Dec 12, 2023
AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Mar 07, 2024 going ex on Feb 15, 2024
Feb 16, 2024
Mar 07, 2024
Feb 15, 2024
Mehr Anzeigen
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
